Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/DuPont Is Timely Deal: Will Disrupt Difficult 2002, Add To 2003

Executive Summary

The Bristol/DuPont deal may offer Bristol-Myers Squibb a healthy dose of distraction heading through a difficult period of patent expirations.

You may also be interested in...



Watson Oxytrol Launch Planned For Mid-2002 As Firm Shifts Focus To Brands

Watson plans to use a marketing partner or contract sales organization to launch its overactive bladder transdermal patch Oxytrol (oxybutynin)

Watson Oxytrol Launch Planned For Mid-2002 As Firm Shifts Focus To Brands

Watson plans to use a marketing partner or contract sales organization to launch its overactive bladder transdermal patch Oxytrol (oxybutynin)

Bristol Decreasing Reliance On Third-Party R&D, Focusing On In-House Efforts

Bristol-Myers Squibb will decrease its dependence on externally sourced development compounds as it ramps up an internal R&D effort, Chief Scientific Officer Peter Ringrose, PhD, said during a Nov. 7 investor update in New York City

Related Content

UsernamePublicRestriction

Register

PS037976

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel